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Exosomes are extracellular nanovesicles (30–100 nm) generated from endosomal
membranes and known to be released by all cell lineages of the Central Nervous
System (CNS). They constitute important vesicles for the secretion and transport
of multilevel information, including signaling, toxic, and regulatory molecules. Initially
thought to have a function merely in waste disposal, the involvement of exosomes
in neuronal development, maintenance, and regeneration through its paracrine and
endocrine signaling functions has drawn particular attention in recent years. These
vesicles, being involved in the clearance and cell-to-cell spreading of toxic molecules,
have been naturally implicated in aging, and in several neurodegenerative diseases
associated with pathological conversion of proteins, as well as in the transport of other
disease-associated molecules, such as nucleic acids or pro-inflammatory cytokines. Our
understanding of such unique form of communication may provide not only answers
about (patho)physiological processes in the brain, but can also offer means to exploit
these vesicles as vehicles for the delivery of biologically relevant molecules or as tools to
monitor brain diseases in a non-invasive way. A promising field in expansion, the study of
exosomes and related extracellular vesicles has just commenced to unveil their potential
as therapeutic tools for brain disorders as well as biomarkers of disease state.
Keywords: exosomes, extracellular vesicles, neurodegeneration, cell-to-cell transmission, biomarkers
INTRODUCTION
Among intracellular organelles, eukaryotic cells also contain organelles that are released into the
microenvironment. These membranous extracellular vesicles can be classified according to their
size into exosomes, ectosomes, and apoptotic blebs (Mathivanan et al., 2010), many of which exhibit
pleiotropic biological functions. In particular, exosomes were initially thought to act as cellular
waste disposal compartments because of their extrusion from the cell, but it was only recently
discovered that exosomes contain not only cellular proteins but also act as natural carriers of nucleic
acid material in the form of DNA, mRNA transcripts, miRNA, and noncoding RNA (Schorey and
Bhatnagar, 2008). They are released under normal as well as pathological conditions and since, have
been recognized as a critical messenger for short and long-distance cell-to-cell communication.
As such, cells use exosomes in the central nervous system (CNS) as a major route of secretion in
order to get rid of waste membranes, harmful RNA or proteins or, more importantly, to act as
messengers, and signal carriers to other neural cells, modifying their function in normal physiology
as well as in states of disease (Zappulli et al., 2016). In this regard, given their ability to mediate
intercellular communication, exosomes are increasingly being considered as one of the actors in
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transporting pathological misfolded proteins that are involved
in neurodegenerative diseases and in disseminating disease into
and within the brain. Nevertheless, since exosomes would be
capable of transporting drugs across the blood brain barrier, their
therapeutic potential has generated great interest in the field.
EXOSOMES AND INTERCELLULAR
COMMUNICATION
Studies in a variety of model systems have provided insights
about origin, composition, and functions of exosomes. The
physiological role of these vesicles is to transport biomolecules
between different cells, being considered as a mechanism
of paracrine (and possibly endocrine) communication.
However, most of the experimental investigations are related to
pathophysiological conditions and disease models, from which
the physiological function has been inferred. Therefore, it has
been assumed that the function of exosomes is maintained
during physiological and pathological conditions, although
further basic studies about their role would be key to corroborate
this assumption.
Exosome Biogenesis
Three main types of vesicles have been described so far:
exosomes, ectosomes and apoptotic blebs. Exosomes range from
30 to 100 nm in diameter, whereas ectosomes range between
50 and 1000 nm and apoptotic blebs, released by dying cells,
between 50 and 5000 nm. Among them, the best characterized
ones are exosomes. Exosomes are membrane-bound spherical
nanovesicles of endocytic origin that are released by almost
all cell types, and which can be found in abundance in body
fluids (Simpson et al., 2008). The biogenesis of exosomes
begins with the invagination of endosomal membranes to form
multivesicular bodies (MVBs) containing intraluminal vesicles
(ILVs) that range from 30 to 100 nm in diameter (Simons
and Raposo, 2009). MVBs can either fuse with lysosomes for
cargo degradation, or with the plasma membrane, which leads
to the release of the ILVs to the extracellular space as exosomes
(Mathivanan et al., 2010).
Exosome Membrane Markers
General markers for exosome include enrichment in CD9,
CD63, CD81, and Heat Shock Cognate 70 (HSC70) proteins,
as well as the embryonic stem cell marker Nanog (Sheller
et al., 2016). As described in this study, a combination of
differentmethods is used to accurately characterize the exosomes;
electron microscopy for shape and morphology, particle sizing,
western blot and flow cytometry for detection of specific
markers and cargo contents, and UV absorbance for DNA
quantification. Altogether, a high-quality isolation method for
exosomes, followed by their characterization and identification,
is mandatory to distinguish exosomes from other microvesicles.
Exosome Cargo Markers
The characterization of exosomal cargo will vary depending on
the cell type that releases the exosome, and although the diversity
in the cargo profile suggests different mechanisms of selection,
there is still no study about the molecular details nor whether
it is a random event. The myriad of results obtained from the
studies that focus on the characterization of exosome content
are gathered in different databases such as Exocarta, EVpedia, or
Vesiclepedia (Mathivanan and Simpson, 2009; Kalra et al., 2012;
Mathivanan et al., 2012; Simpson et al., 2012; Kim et al., 2013).
They provide information about the protein, lipid or acid nucleic
content of the different types of exosomes. Despite the variety
in isolation techniques and different cell types used in these
studies, it seems that a significant number of the proteins found
in exosomes come from the biogenesis process, as it happens
for components of the endosomal sorting complex for transport
(ESCRT) pathway, Rab proteins needed for the formation and
release of vesicles (Rab27A, Rab11B, ARF6), or the tetraspanins
CD9, CD63, and CD81.
Cargo loading into the exosomes can be achieved by different
mechanisms, although protein binding to the plasma membrane
and its subsequent oligomerization seems to be the main process
for cargo acquisition. However, any protein that binds to an
exosome cargo could potentially be loaded into the nascent
exosomes, as it is the case for RNAs, which typically exist in
complex with proteins. Therefore, the selective trafficking of
these macromolecules is linked to the delivery of their binding
partners. Alternatively, cargo proteins can be covalently linked to
exosomes (Yang and Gould, 2013).
Lipids are also loaded into exosomes as cargoes, in which
case they share many characteristics with the lipid membranes
of their cells of origin. Their main differential characteristic
is the enrichment in phosphatidylserine in the outer face of
the exosomal membrane, which facilitates the internalization by
recipient cells (Subra et al., 2007; Fitzner et al., 2011).
Regarding nucleic acids, exosomes are enriched in small RNAs
as compared with DNA, although almost any type of RNA
has been found in these vesicles (Abels and Breakefield, 2016).
However, the profile of the RNA content in exosomes differs
substantially from that of the total cell (Guduric-Fuchs et al.,
2012; Jenjaroenpun et al., 2013; Yagi et al., 2016). Similarly,
the analysis of different secretomes led to the conclusion that
exosomes derived from mesenchymal stromal cells (MSCs)
in the bone marrow enhance neurite growth, as opposed to
microvesicles or total secretome. The differential profiles in
exosomal cargo content found in this study suggest that selective
mechanisms underlie the processes of cargo selection and/or
reception, which are still unexplored, and could open the door to
the development of new therapeutic tools (Lopez-Verrilli et al.,
2016).
Exosome Release and Transmission
Although poorly investigated, exosome release is thought to be
affected by other cellular events, and it has been described that
synaptic glutamatergic AMPA and NMDA receptors modulate
exosome release in differentiated neurons (Lachenal et al., 2011).
Indeed, neuronal depolarization and calcium influx events into
the neuron after ionomycin treatment enhanced exosome release
(Lachenal et al., 2011), suggesting that this is an event that can be
modulated and therefore suitable to be developed as a therapeutic
tool. Several other works have confirmed the role of exosomes
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in modulating synaptic activity, as for example the polarized
delivery of exosomes at synapses (Mittelbrunn et al., 2015).
Also, endocannabinoids, which are secreted through extracellular
vesicles produced by microglia, are able to inhibit presynaptic
transmission (Gabrielli et al., 2015). Exosomes can indeed act as
novel mechanisms of trans-synaptic communication, in which
synaptogenic factors such as the presynaptic protein Evi are
released into the synaptic cleft via these vesicles (Korkut et al.,
2009).
Another rising issue in exosome research is that most
of the studies use scenarios where a certain biomolecule is
overexpressed, due to technical requirements or to the specific
pathology that is being studied. It has to be pointed out that
overexpression techniques can lead to a forced transmission
event that otherwise would not occur in physiological conditions.
This concern, together with the fact that exosome release is
seldom the primary route of cell-to-cell transmission, question
whether exosomes are a complementary but not necessary
mechanism of paracrine/endocrine communication.
Once delivered, exosomes are taken up by the recipient cell,
in a process that involves fusion with the plasma membrane,
and different mechanisms of endocytosis that depend on the
cell type (Abels and Breakefield, 2016). For example, in the
CNS, neurons internalize exosomes through clathrin-dependent
endocytosis or phagocytosis (Feng et al., 2010; Fruhbeis et al.,
2013), while microglia internalizes these membrane vesicles
through macropinocytosis (Fitzner et al., 2011). The uptake
may depend on the cellular state of the recipient cell, since
surface ligands recognize receptors on the exosome. However, an
important question that remains unanswered about extracellular
vesicles is whether the recipient cell has any role in the selection
of the receiving cargo, or if this only depends on the emissary
cell. Other factors that modulate the uptake of exosomes is the
presence of heparin sulfate proteoglycans (HSPGs) on the plasma
membrane (Atai et al., 2013; Christianson et al., 2013), or the
blockage of specific receptors on the plasma membrane, as it was
described for SR-B1 receptor (Plebanek et al., 2015).
EXOSOMES IN NEURODEGENERATIVE
DISEASES
Intercellular communication is a cornerstone in the research
of neurodegenerative diseases. Beyond the complex molecular
events that take place within the cell, the effects that these
can have on neighboring or distant cells are a matter of
intense investigation. This is mostly because communication
often happens through the extracellular space, the compartment
where it is easier to intervene, either by using a therapeutic
tool to modify the disease, or by probing and sampling to
diagnose or assess disease progression. During the last decade,
among the several mechanisms for cell communication studied in
neurodegenerative diseases, exosomes and extracellular vesicles
have emerged as common players. Clearance and disposal of
byproducts or toxic molecules, as well as cell-to-cell transmission
of nucleic acids, cytokines and enzymes, but also aggregated or
misfolded proteins, are among the several cargos being studied
in brain pathophysiology (Figure 1). At this time, most of the
advances have been achieved in vitro, but the results are vastly
interesting, particularly for the prion-like spreading hypothesis
applied in the understanding of neurodegenerative diseases.
Prion Diseases
Prions are infectious agents consisting of proteins misfolded into
aberrant conformations that can transmit their misfolded state to
“naïve” proteins of the same type and aggregate with themselves
into oligomers and fibrils. According to the prion hypothesis
(Prusiner, 1982), these infectious particles operate, thus, as
proteopathic seeds that trigger a chain-reaction of refolding
and self-aggregation, spreading the pathophysiological status
to other cells, and ultimately causing neurodegeneration and
loss of gray matter. Transmissible spongiform encephalopathies
such as Creutzfeldt-Jacob disease in humans or scrapie in
animals, are known to originate from this mechanism (Collinge,
2001). Similarly, in other neurodegenerative diseases such as
Alzheimer’s or Parkinson’s Disease there is also a progressive
accumulation of misfolded proteins such as β-amyloid, tau,
and α-syn, among others, which occurs concomitantly with
the spreading of the pathology between neuroanatomically
connected regions. These characteristics have led to the
hypothesis that these and other proteinopathies share a common
originating mechanism, which has given rise to the “prion-like”
hypothesis (Jucker and Walker, 2013).
The idea of exosome-mediated propagation in prion diseases
was introduced in the last decade, when Fevrier et al. (2004)
found that the prion protein (PrP)-expressing cells could
release PrPC (normal) and PrPSc (abnormal) in association with
exosomes. The first report that linked in vivo the prion disease
pathogenesis and exosomes came 4 years later, when Vella et al.
(2008) found PrPC associated to extracellular vesicles in the CSF
of sheep. The interplay between prions and exosomes has just
begun to be unveiled in recent years: The biogenesis of exosomes
appears to be implicated both in the conversion of PrPSc (Yim
et al., 2015) as well as in its packaging (Vella et al., 2007).
Moreover, PrPSc can apparently alter the structure (Coleman
et al., 2012) and cargo (Bellingham et al., 2012b) of exosomes,
and upregulating the exosomal secretion pathway increase the
infectiousness of PrPSc (Guo et al., 2016).
Alzheimer’s Disease: β-Amyloid and Tau
Rajendran et al. (2006) first described in vitro the intracellular
β-cleavage of the amyloid precursor protein (APP) in early
endosomes, and the subsequent secretion of β-amyloid (Aβ) to
the extracellular space via exosomes, suggesting a role of these
vesicles in Aβ propagation. There have been no further reports
associating exosomal secretion to Aβ spreading, but APP-C-
terminal fragments have been found, indeed, in exosomes in vitro
(Sharples et al., 2008) and in vivo (Perez-Gonzalez et al., 2012),
which at least suggests a role of the exosomal secretory pathway
in the generation of Aβ. Nonetheless, consensus within the field
seems to be that direct cell-to-cell transmission is more prevalent
than exosome-mediated transfer for the pathological spreading
of Aβ (Bellingham et al., 2012b).
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FIGURE 1 | Exosomes: biogenesis, composition, and function. Exosomes are released upon fusion with the plasma membrane of multivesicular bodies (MVBs),
which are constituted by intraluminal vesicles (ILVs) from the secretory (ER, Golgi) and/or endocytic pathways. Exosomal cargoes range from nucleic acids (mRNAs
and miRNAs), cytokines and enzymes (IL-1β, proteases) to misfolded proteins (α-synuclein, SOD1, PrP) in their monomeric and/or oligomeric forms. These molecules
can be carried either in the exosomal lumen or embedded in its membrane. Exosomes released to the extracellular space display a variety of markers, such as
tetraspanins CD9, CD63, and CD81 or heat shock cognate 70. Intercellular communication is effectively achieved upon uptake by the receptor cell, either facilitated
by clathrin-mediated endocytosis or by pinocytosis. Receptor cells can be in the nearby region (paracrine) or further beyond (endocrine). Clearance of toxic molecules
contained within exosomes, such as β-amyloid, is thought to be mediated by microglia and macrophages.
However, conflicting reports exist about the stabilization of Aβ
toxic species inside MVBs. Some authors suggest that exosomes
promote aggregation of Aβ, serving as nucleation hubs for
plaque formation (Dinkins et al., 2014; Falker et al., 2016).
This hypothesis would render exosomes as neuroprotective
compartments, which clear toxic oligomeric species of Aβ in
favor of the more stable and less toxic fibrils. In contrast, others
propose that exosomes can indeed induce the disassembly of
stable species into neurotoxic oligomers (Yuyama et al., 2012;
Joshi et al., 2014), depending on whether the exosomes are of
neuronal or myeloid origin, based on the idea that different
membrane lipid compositions might affect Aβ assemblies.
Hyperphosphorylated misfolded tau, the primary component
of neurofibrillary tangles and a cytopathological hallmark of AD,
is associated to exosomes in the CSF of AD patients (Saman
et al., 2012). Several in vitro studies where tau is overexpressed
suggest that this microtubule-associated protein is secreted via
exosomes (Chai et al., 2012; Simon et al., 2012), and transmitted
trans-synaptically through the extracellular space (Lee et al.,
2012; Liu et al., 2012), which proposes a mechanism for the
progressive spreading of tauopathy in the brain of AD patients.
Indeed, inhibition of exosomal secretory pathways reduces the
propagation of Tau in vitro and in vivo (Asai et al., 2015) in a
viral-mediated expression model. On the contrary, secretion of
endogenous tau is regulated by neuronal activity (Pooler et al.,
2013; Wu et al., 2016), and this physiological process appears to
be exosome-independent (Pooler et al., 2013). Additional work
in more intact preparations that avoid the possible artifacts from
tau overexpression, is necessary to shed light into this subject.
The relevance of exosomes in proteinopathies should not
only be explored from the point of view of intercellular
transmission of proteopathic seeds. Indeed, there is still debate
in the field about whether the pathological trait is transmitted
by the misfolded protein itself, the so-called “prion-like” self-
propagation, or other signals induce the aberrant folding in
selectively vulnerable neurons (Walsh and Selkoe, 2016). Indeed,
a recent study showed that misfolded seeds can be found all over
the brain, still suggesting a propagation of proteopathic seeds,
while only a subset of the brain will indeed display aggregation
and neurodegeneration (Alibhai et al., 2016). Looking into the
problem from the latter perspective, exosomes might be carriers
of molecules such as nucleic acids or enzymes that could exert
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a pathophysiological modification in an endocrine manner. For
instance, secretion of enzymes that degrade Aβ are associated to
exosomes (Bulloj et al., 2010; Tamboli et al., 2010), and miRNAs
transported within neuron-derived exosomes can activate glial
cell functions, such as activation of microglial phagocytosis for
the clearance of neurodegenerating dendrites (Bahrini et al.,
2015). Furthermore, microglial and neuronal exosomes have
been proposed to participate in the disposal of Aβ in the brain
(Yuyama et al., 2012, 2015), a concept that becomes further
relevant given that impaired Aβ clearance is a characteristic of
AD (Mawuenyega et al., 2010). Altogether, the current state-of-
the-art in the field shows that not only cell-to-cell transmission,
but also exosome-mediated communication and clearance might
be important players in AD.
Parkinson’s Disease and Other
Synucleinopathies
Alpha-synuclein (α-syn) is a major component of Lewy bodies
(Spillantini et al., 1997), the neuropathological hallmark of
Parkinson’s Disease (PD) and Dementia with Lewy bodies (DLB).
α-Syn is a pre-synaptic protein that exists in an equilibrium
between monomeric and oligomeric states. Mutations and other
disease-related factors affect the aggregation dynamics, favoring
the balance toward fibrillization (Dehay et al., 2015). The
neurodegenerative process observed in PD spreads through
anatomically interconnected regions in the CNS (Braak et al.,
2003), and the pathogenic trait of misfolded α-syn is thought to
propagate through a prion-like process (Olanow and Prusiner,
2009; Lee et al., 2010). Very recently, a team demonstrated that
exosomal α-syn species isolated from the CSF of PD and DLB
patients is able to promote aggregation of α-syn (Stuendl et al.,
2016). However, whether exosomes play a role in α-syn spreading
is still a matter of debate.
Among all proteopathic seeds, most reports of secretion
associated to exosomes and related vesicles belongs to the α-
syn field (Emmanouilidou et al., 2010; Alvarez-Erviti et al.,
2011a; Danzer et al., 2012; Kong et al., 2014; Shi et al., 2014;
Tsunemi et al., 2014). The first report that identified α-syn
showed that this is a protein present in synaptic vesicles.
Due to its cellular function, a link to exosomes might be
related to its intrinsic function within the exocytic machinery
at the pre-synaptic terminal (Bendor et al., 2013). Despite the
fact that the physiological role of α-syn is not completely
understood, it has been suggested that α-syn is involved in
synaptic vesicular processing (Vargas et al., 2014), where it binds
to the membrane and undergoes conformational changes that
facilitate the generation of the vesicle curvature (Varkey et al.,
2010; Westphal and Chandra, 2013). It has also been reported
that α-syn prefers membranes with high curvature (Jensen et al.,
2011), like the ones found in the 50–100 nm exosomes. It is
worth to note that non-monomeric, i.e., aggregated α-syn, is
unable to perform this task, and it is not clear whether membrane
association induces or prevents oligomerization (Bendor et al.,
2013). In the first study that characterized the secretion of α-syn
by unconventional secretory pathways, Lee et al. (2005) already
discussed that its compartmentalization into vesicles could
promote the misfolding of α-syn. A recent study demonstrated
that exosomes accelerate α-syn aggregation (Grey et al., 2015),
and that the lipid composition of the vesicles is critical for
this process. The mechanism by which α-syn is incorporated
into exosomes is still unknown, but given the vast number of
genes linked to PD that have a role in endocytic and autophagy
pathways such as PARK2, GBA, LRRK2, or ATP13A2 (Gan-
Or et al., 2015), the rapid advancement of research in vesicle
trafficking might give some clues in the next years.
In multiple system atrophy (MSA), oligodendrocytes
forming α-syn-containing aggregates named glial cytoplasmic
inclusions (GCIs) accumulate α-syn, which is accompanied
by demyelination and extensive dopaminergic neuronal loss
throughout the brain. Although transgenic MSA models
overexpressing α-syn under different oligodendrocyte-specific
promoters have been studied for a decade (Fernagut and Tison,
2012), the link between oligodendroglial α-syn aggregation
and neuronal death remains elusive. Moreover, as α-syn is
a predominantly neuronal protein, it is also unknown if
oligodendrocytes in a disease state can synthesize α-syn de
novo, or if α-syn is readily transferred from neurons. In this
regard, there are several reports indicating that oligodendrocytes
and neurons communicate via exosomes, which supports
the hypothesis of α-syn transfer between these two cell types
(Kramer-Albers et al., 2007; Bakhti et al., 2011). This exosomal
communication between neurons and oligodendrocytes includes
the transfer of genetic information by miRNAs (Fruhbeis et al.,
2013), which in fact are altered in MSA (Ubhi et al., 2014;
Schafferer et al., 2016). Therefore, a potential involvement of the
exosomal secretory pathway in the pathogenesis of MSA should
not be overlooked.
Amyotrophic Lateral Sclerosis and
Huntington’s Disease
Amyotrophic lateral sclerosis (ALS) is characterized by the
misfolding of Cu/Zn superoxide dismutase (SOD1) into aberrant
conformations, which has been pinpointed as a central event
in familiar and sporadic forms of the disease (Bosco et al.,
2010). In vitro, neurons secrete exosomes loaded with mutant
SOD1 to the extracellular space (Gomes et al., 2007), where
these exosomes are able to transmit the pathogenic trait to
other neurons, and propagate the misfolding of SOD1 (Grad
et al., 2014). Furthermore, astrocytes also secrete SOD1-loaded
exosomes that are selectively toxic for motor neurons (Basso
et al., 2013), showing that exosome-mediated transfer of mutant
SOD1 is pathogenic.
TDP-43 is a nuclear protein that mislocalizes to the cytoplasm,
aggregates and forms inclusions in ALS and in fronto-temporal
dementia (FTD). Dipeptide repeat proteins (DPRs) are produced
by the unconventional translation of the C9orf72, the most
common mutated gene in ALS and FTD as well. Recently,
both molecules have been associated with exosomal release and
transport (Nonaka et al., 2013; Ding et al., 2015; Westergard
et al., 2016), further suggesting a link between exosome-mediated
communication and the disease.
Exosomes can also propagate toxic molecules in an inter-
species manner. An interesting work showed recently a cell-
to-cell propagation of mutant Huntingtin (mtHtt) in exosomes
using 143 CAG repeats fibroblasts and SH-SY5Y neuroblastoma
cells. Furthermore, injecting newborn wild-type mice with
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human exosomes carrying mtHtt triggered Huntington disease-
like (HD) symptoms and pathology in these animals (Jeon et al.,
2016), this being the first report of human-to-mouse exosome-
mediated propagation of toxic molecules.
Multiple Sclerosis and Inflammation
Inflammation is a central player in most neurodegenerative
diseases. Neuroinflammatory processes exert profound changes
not only in the vicinity but beyond the local environment of
cells. In addition to the propagation of toxic proteins, exosomes
also carry important inflammatory modulators, such as mRNAs,
miRNAs, and cytokines (Gupta and Pulliam, 2014). Microglia,
the resident macrophages of the CNS, can shed exosomes loaded
with pro-inflammatory molecules such as IL-1β (Bianco et al.,
2005) and other cytokines. Their scavenging functions are also
crucial in the clearance of toxic seeds such as Aβ (Yuyama
et al., 2012). Furthermore, endocrine signals from hematopoietic
cells directed to the brain can be transported by exosomes, a
phenomenon that is augmented in a context of inflammation
(Ridder et al., 2014). It is interesting to note that extracellular
vesicles can readily cross the blood brain barrier, adding a
communication channel by which systemic inflammation can
modulate physiological processes in the CNS.
Multiple sclerosis (MS) is a demyelinating disease
characterized by the loss of oligodendrocytes, where
inflammation plays a prominent role (Compston and Coles,
2008). Increased levels of circulating exosomes are present in
the inflammation-driven disease model of MS, experimental
autoimmune encephalomyelitis (EAE). In this model, pro-
inflammatory cytokines promote exosome release by immune
cells, which in turn carry more pro-inflammatory molecules,
spreading inflammation. Animals where exosome-release
activity had been hampered showed reduced inflammation and
EAE symptoms (Verderio et al., 2012). Another component in
the pathogenesis of EAE is glutamate excitotoxicity (Pitt et al.,
2000), which is characterized by pathological accumulation of
this neurotransmitter and amino acids, among other features.
Glutamate can indeed trigger the release of exosomes by
oligodendrocytes (Fruhbeis et al., 2013), cells whose homeostasis
is known to be altered in demyelinating diseases (Matute
et al., 2001). These oligodendrocyte-derived exosomes regulate
axon myelination (Bakhti et al., 2011). Nevertheless, despite
accumulating evidence suggesting a role of exosomes in
inflammatory processes during pathology, whether these
extracellular vesicles participate in the interplay between
inflammation and excitotoxicity in demyelinating diseases
remains unanswered.
EXOSOMES AS THERAPEUTIC AND
DIAGNOSTIC TOOLS
Potential of Exosomes As Carriers for
Disease-Modifying Strategies
Although the exact mechanism of exosomal entry into the
brain is not fully understood, it should be noted that exosomes
are able to cross the blood brain barrier (Record et al., 2011;
Tominaga et al., 2015), rendering them as ideal vehicles to
delivery molecules into the brain (Figure 2). Exosomes are
able to transfer mRNAs, microRNAs or proteins, and they
are thought to be an exchange mechanism between cells
(Valadi et al., 2007; Simpson et al., 2008), suggesting that
these vesicles could be a new delivery machinery especially
for RNA interference (RNAi; Valadi et al., 2007; Simons and
Raposo, 2009). Indeed, RNAi-based technologies need vectors,
since siRNAs can be degraded by extracellular endonucleases
present in the serum, cells or extracellular space, and are also
immunogenic (Whitehead et al., 2011; Kalani et al., 2014).
Regarding delivery, exosomes harbor interesting advantages
over other delivery systems such as liposomes, since they have
a prolonged half-life and no immunogenicity (Kalani et al.,
2014).
The pioneer work of Alvarez-Erviti and coworkers has
shown that exosomes can be engineered to target specific
tissues (Alvarez-Erviti et al., 2011b). They inserted brain- or
muscle-specific peptides in one of the most abundant exosomal
membrane proteins: the lysosomal-associated membrane protein
2b (LAMP-2B). In the brain, the proof-of-concept was obtained
by using exosomes that contain siRNA for brain-specific
knockdown of BACE1, encoding the beta-secretase 1 enzyme, in
wild type mice (Alvarez-Erviti et al., 2011b). In a more recent
study, the same strategy was successfully used to knockdown
α-syn in transgenic mouse brain (Cooper et al., 2014). Altogether,
these results suggest that exosomes might be interesting vehicles
for RNAi delivery. As exosomes are able to target most
brain cell types, these results pave the way to applicability
in other diseases associated to α-syn accumulation, such as
MSA.
microRNAs are highly abundant and largely studied in the
biology of exosomes, in part due to their importance in the
regulation of gene expression. Therefore, delivery of miRNAs-
containing exosomes can constitute a precious therapeutic tool
(Ohno et al., 2013). In this sense, MSCs release exosomes
that contain overexpressed miRNA-133b, which was found to
improve the recovery of ischemic (MCAO) rats, including neurite
remodeling in the infarcted area (Xin et al., 2016). The authors
used in vitro exosomes from MSCs along with overexpression
of miR-133b+, which increased the release of exosomes from
oxygen and glucose-deprived astrocytes. These experiments
resulted in increased neurite branching, which suggests that
secondary astrocyte release may contribute to neuronal plasticity
and recovery after stroke. It should be noted that whereas in vivo
MSCs are in charge of miRNA-containing exosome release, Xin
et al. used astrocytes for the in vitro studies, a different cell type
where the role and function of miRNAs might be substantially
different. Interestingly, five miRNAs from the exosome-released
pool showed differential expression levels during traumatic
brain injury (TBI), for which miR-21 showed the larger change
(Harrison et al., 2016). The authors hypothesize that the increase
in miR-21 is due to its release in neuronal exosomes close to
the injury boundary, in which vicinity reactive microglia was
found.
Engineered nucleic acids, such as hydrophobically modified
small interfering RNAs (hsiRNAs) have been shown to load
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FIGURE 2 | Exosomes as therapeutic and diagnostic tools. Targeting the exosomal secretory pathway in neurodegenerative diseases has been proposed as a
disease-modifying strategy, since it can reduce the propagation of proteopathic seeds and other toxic molecules. Exosomes can also serve as biomarkers, since they
carry molecules relevant for diagnosis, such as disease-related proteins or unique sets of miRNAs (a proposed “signature” or “bar-code”). Finally, the resilience of
exosomes in the extracellular milieu renders them as ideal vehicles for the delivery of drugs or disease-modifying molecules such as viral DNA or siRNAs, with the
possibility of being targeted to specific cell types or tissues by genetic engineering of membrane proteins.
into exosomes (Didiot et al., 2016) and they constitute
another example of the therapeutic potential of exosomes.
In this work, hsiRNAs targeting Huntingtin (Htt) mRNA
were efficiently internalized by primary cortical neurons in
a dose-dependent manner, where they silenced up to 35%
of Htt mRNA. Lastly, exosomes can also be carriers for
neuron-specific rabies viral glycoprotein (RVG) peptide on the
membrane, which delivers opioid receptor mu (MOR) siRNA
into the brain associated with argonaute 2 (AGO2; Liu et al.,
2015).
In addition to nucleic acids, exosomes have been successfully
used to deliver drugs (Tian et al., 2014), and exosomes filled
with anti-inflammatory compounds such as curcumin have been
successfully administered to the brain through an intranasal
route (Zhuang et al., 2011). In this experiment, microglia
internalized exosomes within 60min after delivery, and exosome-
delivered curcumin successfully attenuated EAE symptoms.
Although the distribution was mostly limited to olfactory bulbs,
these results suggest that exosomes could be used broadly as
molecule carriers for neurological disorders.
Targeting Exosomes As a
Disease-Modifying Strategy Itself
As mentioned earlier, exosomes are involved in the cell-to-cell
transmission of neurodegenerative-related proteins. Indeed,
several reports highlight that PrP, tau or α-syn can be released
in exosomes (Lee et al., 2005; Aguzzi and Rajendran, 2009;
Emmanouilidou et al., 2010; Saman et al., 2012). Taking into
account the propagation of α-syn as an example, the total
amount of α-syn in exosomes is low under basal conditions
(Emmanouilidou et al., 2010). However, in pathological
conditions exosomes could allow spreading between cells of
pathological misfolded α-syn. This “Trojan-horse” hypothesis
leads to hypothesize that targeting exosome release might be a
promising strategy to block disease propagation and progression
(Figure 2). Future studies are still needed to unravel the
relevance of such mechanism, as well as the molecular machinery
underlying the import of neurodegenerative-related proteins
into exosomes. Furthermore, targeting the exosomal secretory
pathway without affecting its physiological communicational
role might not be an easy task, and further work onto the basic
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physiological mechanisms of exosome release and cargo selection
will be crucial in this matter.
Exosomes As Biomarkers for Disease
Since the identification of neurodegenerative disease related
proteins in exosomes, these vesicles have been proposed as
putative biomarkers to monitor disease progression (Figure 2).
Exosomes can be isolated from multiple fluids including urine,
blood or cerebrospinal fluid (CSF), which facilitates their clinical
use as biomarkers (Street et al., 2012; Cheng et al., 2014a,b).
Quantifications of neurodegenerative disease related proteins
in total CSF or in exosomes purified from CSF have led to
contradictory results in both AD and PD (Parnetti et al., 2013;
Kim et al., 2016; Vella et al., 2016). Interestingly, a report
has shown that hyperphosphorylated-tau (often considered as
pathological tau) in exosomes is significantly increased in
patients with mild forms of AD compared to controls (Saman
et al., 2012). Although such result suggests that measuring tau
phosphorylation in exosomes could be used as a biomarker
for AD, the fact that moderate or severe forms of the disease
do not show similar phosphorylation levels dampens that
hypothesis. One possible explanation could be that high levels
of phosphorylated tau in exosomes is specific of a disease-stage,
and not the entire pathological process. Regarding PD, similar
divergences are also present in the literature. Indeed, a report
showed that α-syn is increased in microvesicles for PD patients
while another did not observed variation in the α-syn content
(Shi et al., 2014; Tomlinson et al., 2015). This discrepancy could
be explained by technical differences as well as differences in the
patient population.
As many other proteins are present in exosomes, recent
initiatives have used large-scale methodologies to analyze
exosome content. Usingmass-spectrometry to analyze circulating
microvesicles, it was identified that PD patient fibroblasts are
enriched in syntenin 1, a regulator of exosome biogenesis
(Tomlinson et al., 2015). Similarly, a set of nine miRNAs have
been shown to be distinct in exosomes purified from control
and prion-infected cells (Bellingham et al., 2012a), defining a
molecular “signature” that can identify a pathological process.
Although the relevance of such hits in the disease is not
established yet, these approaches suggest that establishing a “bar-
code” from the exosomal profile of patients might be a more
valuable diagnostic tool than quantifying specific disease-related
proteins, which are often mixed at early disease stages.
Exosomes can originate from most cell types and have been
identified in most body fluids. A study identified the Leucine-
Rich Repeat Kinase 2 (LRRK2), a protein involved in some
hereditary forms of PD, in urinary exosomes (Fraser et al.,
2013). The strong variability observed in clinical populations
argued against its use as a biomarker for PD. However, one
can hypothesize that exosomes originating from brain might
be diluted in body fluids containing exosomes originating from
other organs. To test this hypothesis, a recent study used
an immunochemical method to purify brain exosomes from
peripheral blood plasma (Shi et al., 2014). The authors reported
an increase of α-syn specifically in exosomes from plasma of
PD patients (i.e., no overall modification was observed in total
plasma). Although this approach was developed to be brain-
specific based on the expression of the L1-cell adhesion molecule
(L1-CAM), this protein is also expressed in the renal system
(Allory et al., 2008; Vella et al., 2016), therefore these results
have to be taken carefully. However, and more importantly,
the immunochemical capture method provides an innovative
approach for quantifying neurodegenerative disease related
proteins in peripheral fluids to be used as biomarkers, and which
hold the promise of a better specificity (Vella et al., 2016).
Interestingly, insulin resistance (i.e., decreased insulin/insulin
like growth factor IGF-1 signaling) has been established in both
MSA patients and in a well-characterized transgenic model, the
PLP-SYN mice (Bassil et al., 2017). Insulin resistance can be
measured by analyzing the amount of the downstreammessenger
insulin receptor substrate-1 phosphorylated at serine residues
312 (IRS-1pS312) or 616 (IRS-1pS616; Moloney et al., 2010;
Talbot et al., 2012). Since this biomarker can be traced in
peripheral exosomes (Kapogiannis et al., 2015), we evaluated
the murine plasma neural derived exosomal IRS-1pS307 levels
(corresponding to human IRS-1pS312) in transgenic MSA mice
that were treated with the glucagon-like peptide-1 (GLP-1)
agonist exenatide. We found a correlation with the number of
nigral dopaminergic neurons and with striatal oligomeric α-syn
load in transgenic MSA mice, indicating that PLP-SYN mice
with highest plasma exosomal IRS-1pS307 concentrations had
a lower number of nigral TH and Nissl-stained neurons as well
as higher striatal oligomeric α-syn levels (Bassil et al., 2017).
Altogether, these data suggest that peripheral neural derived
exosomal IRS-1pS312 is an exosomal biomarker candidate
that may serve as an objective outcome measure of target
engagement for preclinical studies as well as clinical trials with
GLP-1 analogs and other compounds modulating insulin/IGF-1
signaling.
CONCLUDING REMARKS
The last decade has witnessed a dramatic increase in publications
in the field of exosomes and related extracellular vesicles.
Initially considered waste disposal material, recent evidence has
progressively changed this view, and exosomes are currently
considered, in fact, as a broad intercellular communication
system that can internalize, transport and transfer all types of
biomolecules, from nucleic acids to peptides and proteins.
Most of the research in exosomes and extracellular vesicles
has been carried out in cell cultures. This in vitro approach
has been very useful to screen cell types, cargos, and genetic
backgrounds, providing useful data to understand the biogenesis
and physiological role of exosomes. However, their role
in neurodegenerative diseases, either as carriers of disease-
modifying molecules, or as an effective clearance system, is
yet to be completely understood. Several questions remain
unanswered, mostly because of the lack of in vivo studies, as well
as experiments in more intact preparations where the relevant
molecules are expressed in endogenous levels. Among several
open questions in the field, of particular interest, are (i) whether
exosomes from diseased organisms can effectively propagate the
pathogenic trait in vivo, (ii) whether targeting the exosomal
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secretory pathway can be beneficial for the pathology, and (iii)
what is the molecular profile or “signature” that can be read
from exosomes isolated from patients to be used as biomarkers
in different brain disorders. Future studies will hopefully fulfill
the high expectations raised among neurobiologists regarding the
use of exosomes as therapeutic targets and/or tools.
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